A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma

This is an open label Phase 2 study to evaluate the efficacy and safety of ACR-368 as monotherapy or with ultra-low dose gemcitabine (ULDG) sensitization in participants with endometrial cancer.

Trial Details

NCT ID
NCT05548296
Phase
PHASE2
Sponsor
Acrivon Therapeutics
Status
RECRUITING
Cancer Type
Uterine Cancer
Interventions
  • ACR-368
  • Gemcitabine
  • OncoSignature
Locations (sample)
  • Mobile, Alabama, United States|30.69436,-88.04305
  • Anchorage, Alaska, United States|61.21806,-149.90028
  • Phoenix, Arizona, United States|33.44838,-112.07404
  • Tucson, Arizona, United States|32.22174,-110.92648
  • Little Rock, Arkansas, United States|34.74648,-92.28959

Key Eligibility Criteria

  • Participant must be able to give signed, written informed consent.
  • Participant must have histologically documented, high-grade endometrial cancer.
  • Arms 1 and 2
  • All high-grade epithelial endometrial histological subtypes are eligible including: endometrioid (all Grade 3), serous, carcinosarcomas, clear-cell…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Uterine Cancer Trials on Trialify →